產品詳情
簡單介紹：
Anti-PIRH2抗體產品質量穩定，實驗效果明顯，貨期快，價格優惠，歡迎垂詢訂購！我公司長期供應**組化抗體、WB抗體、**組化試劑盒和抗體試驗所需全部相關試劑、熒光標記抗體、單克隆抗體、多克隆抗體、各種標記的二抗IgG/IgM/IgD/IgA等科研實驗抗體。Anti-PIRH2抗體用于**組化實驗,WB實驗,相應的標記抗體有HRP標記抗體,FITC標記,BIO等。
詳情介紹：
Rabbit Anti-PIRH2
Cat. Number:
Anti-PIRH2抗體KL-4895R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
Pirh2 has p53-induced ubiquitin-protein ligase activity, promoting p53 degradation. The protein physically interacts with p53 and the resulting degradation of p53 renders Pirh2 an oncogenic protein as the loss of p53 function contributes Anti-PIRH2抗體to malignant tumor development. The gene encoding for the protein maps to chromosome 4q21.1 and transcription of this gene is regulated by p53. Pirh2 expression decreases the level of p53 and a decrease of endogenous Pirh2 expression ups p53 levels. Pirh2 is therefore considered, together with MDM2, to be acting as a negative regulator of p53 function.
Also known as:
Androgen receptor N terminal interacting protein; Androgen receptor N-terminal-interacting protein; ARNIP; CH-rich-interacting match with Anti-PIRH2抗體PLAG1; CHIMP; E3 ubiquitin-protein ligase Pirh2; hARNIP; hPirh2; p53 induced protein with a RING H2 domain; p53-induced RING-H2 protein; PIRH2E; PIRH2F; PRO1996; RCHY1; Ring finger and CHY zinc finger domain containing 1 E3 ubiquitin protein ligase; RING finger and CHY zinc finger domain-containing protein 1; RING finger protein 199; RNF199; ZFP 363; Zinc finger protein 363; ZN363_HUMAN.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Dog, Pig,Anti-PIRH2抗體 Cow, Horse, Sheep, .
●
Immunogen: KLH conjugated synthetic peptide derived from human PIRH2.
●
Predicted Molecular Weight: 30kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 Anti-PIRH2抗體
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
